Top-News
Pharmazeutika Dänemark

Novo-Nordisk News

Aktie
WKN:  A3EU6F ISIN:  DK0062498333 US-Symbol:  NONOF
123,74 €
+1,00 €
+0,81%
18:23:02 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
3,48 Mrd.
Marktkapitalisierung *
427,14 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
Stoxx Europe 50
IR-Website
zur Website
*Stand: 13.09.2023
Weiter aufwärts? Long handeln - Jetzt mit Hebel 9,25: VM9174

Ad-hocs

13.05.24 - GlobeNewswire
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-​label, randomised, controlled, ...
02.05.24 - GlobeNewswire
Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024
Bagsværd, Denmark, 2 May 2024 - financial report for the period 1 January 2024 to 31 March 2024
24.04.24 - GlobeNewswire
Novo Nordisk A/S – Reduction of the share capital
Bagsværd, Denmark, 24 April 2024 – At Novo Nordisk’s Annual General Meeting on 21 March 2024, it was decided to reduce the company’s B share capital from DKK 343,512,800 to ...
21.03.24 - GlobeNewswire
Awiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities
Bagsværd, Denmark, 21 March 2024 – Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted ...
21.03.24 - GlobeNewswire
Resolutions from the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 21 March 2024 - Today, Novo Nordisk A/S held its Annual General Meeting.
08.03.24 - GlobeNewswire
Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy ® based on a ...
07.03.24 - GlobeNewswire
Highlights to be presented at Novo Nordisk’s Capital Markets Day 2024
Bagsværd, Denmark, 7 March 2024 – Novo Nordisk is today hosting a Capital Markets Day (CMD) where the company is providing a progress update on its Strategic Aspirations 2025.
05.03.24 - GlobeNewswire
Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop ...
21.02.24 - GlobeNewswire
Notice for the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 21 February 2024 – The Annual General Meeting of Novo Nordisk A/S will be held on:
05.02.24 - GlobeNewswire
Novo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction
Bagsværd, Denmark, 5 February 2024 – Novo Nordisk today announced that the company has agreed to acquire three fill-​finish sites from Novo Holdings A/S (Novo Holdings) in ...
31.01.24 - GlobeNewswire
Novo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023
Bagsværd, Denmark, 31 January 2024 - Financial report for the period 1 January 2023 to 31 December 2023
08.01.24 - GlobeNewswire
COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes
COMBINE 3 phase 3a trial successfully completed with once-​weekly IcoSema demonstrating non-​inferior reduction in HbA 1c versus daily basal-​bolus treatment (insulin glargine ...
02.11.23 - GlobeNewswire
Novo Nordisk's sales increased by 29% in Danish kroner and by 33% at constant exchange rates to DKK 166.4 billion in the first nine months of 2023
Bagsværd 2 November 2023 - Financial report for the period 1 January 2023 to 30 September 2023
13.09.23 - GlobeNewswire
Novo Nordisk conducts a two-for-one stock split
Bagsværd, Denmark, 13 September 2023 – As communicated on 10 August 2023 in connection with the release of Novo Nordisk's financial results for the first six months of 2023, ...
10.08.23 - GlobeNewswire
Novo Nordisk's sales increased by 29% in Danish kroner and by 30% at constant exchange rates to DKK 107.7 billion in the first six months of 2023
Financial report for the period 1 January 2023 to 30 June 2023, 10 August 2023
08.08.23 - GlobeNewswire
Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial
Bagsværd, Denmark , 8 August 2023 – Novo Nordisk today announced the headline results from the SELECT cardiovascular outcomes trial. The double-​blinded trial compared ...
22.05.23 - GlobeNewswire
Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial
Bagsværd, Denmark, 22 May 2023 – Novo Nordisk today announced headline results from OASIS 1, a phase 3a trial in the global OASIS programme. OASIS 1 is a 68-week, efficacy ...
04.05.23 - GlobeNewswire
Novo Nordisk's sales increased by 27% in Danish kroner and by 25% at constant exchange rates to DKK 53.4 billion in the first three months of 2023
Financial report for the period 1 January 2023 to 31 March 2023
28.04.23 - GlobeNewswire
Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 28 April 2023
Bagsværd , Denmark, 2 8 April 202 3 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and ...
26.04.23 - GlobeNewswire
Novo Nordisk A/S – Reduction of the share capital
Bagsværd , Denmark, 2 6 April 202 3 – At Novo Nordisk’s Annual General Meeting on 23 March 2023, it was decided to reduce the company’s B share capital from DKK 348,512,800 to ...

Newssuche

Videos

newspaper
29.05.24
Technical Trading: DAX Long Chance kurzfristig
DAX Long Typ: Turbo Open End WKN: VD5FWS Hebel: 28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »